ClinicalTrials.gg
RecruitingNCT07945275Updated Nov 18, 2026

A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the Treatment of Community-Acquired Pneumonia in Elderly Patients

A Phase 2 interventional study of Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) and Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) in PD Target Attainment Rate, Pneumonia and Elderly (People Aged 65 or More), sponsored by Shandong University. Recruiting at 1 site in China. Open to participants aged 65 Years to 110 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by Shandong University · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.
Updated Nov 18, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
118
Allocation
Randomized
Ages
65 Years to 110 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 142 studies in Pneumonia with a site in China — 44 open to participants now, 48 under way, 2 of them phase 3. Pneumonia · China.

Planned enrollment
57th of 94
118 · median 154
Started
2026
with 12 others
Phase 2
8 of 142
3 open now
Primary completion
2027-05
later than 37 of 47 live
Registered
139th of 142
by date

Among the 142 studies in Pneumonia with a site in China, this one is the 57th largest by planned enrollment of the 94 interventional ones that give a count, is one of 13 that started in 2026, is one of 8 in phase 2, reaches primary completion later than 37 of the 47 other live ones, and was the 139th registered.

Pneumonia

1,569 studies on the registry are indexed under Pneumonia; 267 are open to participants now.

Browse Pneumonia studies →

Open to participants now

44 of the 142 studies in Pneumonia with a site in China are open now. Recruiting first, the newest first:

38 more — sign in →

All 44 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 159 Pneumonia studies recruiting now, 84 (53%) set no upper age limit and 48 (30%) stop at 75 or younger; 40 take children under 18; 23 take healthy volunteers.

This study: 65 Years to 110 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies in Pneumonia with a site in China, or all of them as a file.
02

Study summary

This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection.

Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours.

But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better.

The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule.

Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug.

Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.

03

Conditions studied

  • PD Target Attainment Rate
  • Pneumonia
  • Elderly (People Aged 65 or More)

Browse trials for

04

Who can participate

Ages eligible
65 Years to 110 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 65 years;
  • Clinically diagnosed or highly suspected community-acquired pneumonia (CAP). CAP clinical diagnostic criteria: All three of the following must be met:

Onset in the community setting;

At least one of the following clinical manifestations:

New-onset cough, sputum production, or worsening of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, or hemoptysis; Fever; Signs of pulmonary consolidation and/or moist rales; Peripheral white blood cell count > 10×10⁹/L or \< 4×10⁹/L, with or without left shift; Chest imaging showing new patchy infiltrates, lobar/segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion.

For patients aged ≥ 65 years with a body temperature \< 38°C, the presence of clear clinical signs of pneumonia and abnormal chest X-ray findings will also be considered meeting the inclusion criteria.

  • At least one of the following risk factors for drug-resistant pathogens:

Comorbidities such as chronic cardiopulmonary disease, diabetes mellitus, renal failure, etc.; Use of broad-spectrum antibiotics within the past 3 months; History of repeated hospitalizations or residence in a long-term care facility;

  • Patients are required to initiate intravenous empiric antimicrobial therapy, and piperacillin-tazobactam is considered appropriate empiric treatment.
  • Expected length of hospital stay ≥ 72 hours;
  • Signed form.

Exclusion criteria

Exclusion Criteria:

  • Highly suspected or confirmed fungal pneumonia or viral pneumonia;
  • Concurrent use of broad-spectrum antibiotics with similar antibacterial spectra, including cefoperazone-sulbactam, imipenem-cilastatin, meropenem, biapenem and others;
  • Patients with severe allergy to β-lactams and history of severe adverse reactions;
  • End-stage diseases with expected survival time shorter than the treatment course, such as advanced malignant tumors and end-stage organ failure;
  • Severe renal insufficiency with \<40 mL/min, or patients receiving continuous renal replacement therapy (CRRT);
  • Any other conditions deemed ineligible for enrollment by investigators.

Post-randomization exclusion criteria:

  • Isolated fungal infection;
  • Isolated viral infection;
  • Patients with confirmed pathogenic bacteria resistant to piperacillin-tazobactam (PIP/TAZO) during the study.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
118 participants (estimated)

Study arms

  • Active comparator
    guideline-based conventional dosing

    Drug: Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)

  • Experimental
    Model-guided optimized dosing

    Other: Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)

Interventions

  • DrugPiperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)

    Control arm (guideline-based conventional dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 3-hour intravenous infusion every 8 hours (q8h), for a total treatment course of 5-14 days.

  • OtherPiperacillin Sodium and Tazobactam Sodium for Injection (Bangda®)

    Intervention arm (model-guided optimized dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 4-hour intravenous infusion every 6 hours (q6h), for a total treatment course of 5-14 days. This arm adopts increased dosing frequency and prolonged infusion duration compared with the control arm.

06

What researchers measure

Primary outcomes

  1. The proportion of patients achieving the predefined pharmacodynamic (PD) target.

    Time frame: up to 1 month

Secondary outcomes

  1. Clinical improvement rate after 3 days of empiric therapy

    Time frame: Day 3

  2. Length of hospital stay

    Time frame: through hospital discharge, an average of 2 weeks

  3. Treatment success rate

    Time frame: through hospital discharge, an average of 4 weeks

  4. Adverse event (AE) incidence rate

    Time frame: through end of study-drug treatment, an average of 7 days

07

Study locations

1 of 1 sites recruiting
  • Shandong Provincial Public Health Clinical Center
    Jinan, Shandong 250000, China
    Recruiting
08

References and documents

Publications

  • Sun J, Yang C, Tang BH, Hao GX, van den Anker J, Wu YE, Sun DQ, Zheng Y, Zhao W. Population Pharmacokinetics and Dosing Optimization of Piperacillin in Elderly Patients with Pneumonia in the Intensive Care Unit. J Clin Pharmacol. 2025 Dec;65(12):1767-1776. doi: 10.1002/jcph.70089. Epub 2025 Aug 5. PubMed 40765209 ↗

Related links

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared due to patient privacy and confidentiality regulations, and the lack of specific informed consent for public data sharing.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for May 2027, 10 months after the start.

Of 40 non-industry phase 2 interventional studies under Pneumonia, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 28. This study's planned 10 months is close to that.

Counting every sponsor, half of 65 studies reached it within 14 months; a quarter within 7 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2026
First posted
Nov 18, 2026
StartActual
Jul 17, 2026
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 18, 2026
Show all 1 update
  1. Nov 18, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07945275
Responsible party
Wei Zhao (Chair, Department of Clinical Pharmacy, School of Pharmacy, Shandong University) — Principal investigator
First posted
Nov 18, 2026
Start date
Jul 17, 2026
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Nov 18, 2026

Study contacts

Wei Zhao
Contact
zhao4wei2@hotmail.com
+8653188383308

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion